Boai NKY Pharmaceuticals Ltd (300109) - Total Assets
Based on the latest financial reports, Boai NKY Pharmaceuticals Ltd (300109) holds total assets worth CN¥4.33 Billion CNY (≈ $633.58 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 300109 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Boai NKY Pharmaceuticals Ltd - Total Assets Trend (2007–2025)
This chart illustrates how Boai NKY Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Boai NKY Pharmaceuticals Ltd for net asset value and shareholders' equity analysis.
Boai NKY Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Boai NKY Pharmaceuticals Ltd's total assets of CN¥4.33 Billion consist of 35.0% current assets and 65.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.8% |
| Accounts Receivable | CN¥307.89 Million | 7.1% |
| Inventory | CN¥318.31 Million | 7.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥174.26 Million | 4.0% |
| Goodwill | CN¥256.35 Million | 5.9% |
Asset Composition Trend (2007–2025)
This chart illustrates how Boai NKY Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Boai NKY Pharmaceuticals Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Boai NKY Pharmaceuticals Ltd's current assets represent 35.0% of total assets in 2025, a decrease from 62.6% in 2007.
- Cash Position: Cash and equivalents constituted 15.8% of total assets in 2025, up from 7.6% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 5.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 7.3% of total assets.
Boai NKY Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Boai NKY Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cngr Advanced Material Co Ltd
SHE:300919
|
China | CN¥83.43 Billion |
|
Luxi Chemical Group Co Ltd
SHE:000830
|
China | CN¥35.95 Billion |
|
Guangdong HongDa Blasting Co Ltd
SHE:002683
|
China | CN¥31.56 Billion |
|
Lily Group Co Ltd
SHG:603823
|
China | CN¥3.49 Billion |
|
Lianhe Chemical Technology Co Ltd
SHE:002250
|
China | CN¥13.79 Billion |
|
Shandong Link Science and Technology Co Ltd
SHE:001207
|
China | CN¥3.22 Billion |
|
Shenzhen WOTE Advanced Materials Co Ltd
SHE:002886
|
China | CN¥3.75 Billion |
|
New East New Materials Co Ltd
SHG:603110
|
China | CN¥822.44 Million |
Boai NKY Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.21 | 2.57 | 1.15 |
| Quick Ratio | 2.57 | 2.02 | 0.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.02 Billion | CN¥1.12 Billion | CN¥163.40 Million |
Boai NKY Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Boai NKY Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.19 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -0.1% |
| Total Assets | CN¥4.37 Billion |
| Market Capitalization | $897.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values Boai NKY Pharmaceuticals Ltd's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Boai NKY Pharmaceuticals Ltd's assets decreased by 0.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Boai NKY Pharmaceuticals Ltd (2007–2025)
The table below shows the annual total assets of Boai NKY Pharmaceuticals Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.37 Billion ≈ $639.22 Million |
-0.09% |
| 2024-12-31 | CN¥4.37 Billion ≈ $639.77 Million |
+8.77% |
| 2023-12-31 | CN¥4.02 Billion ≈ $588.21 Million |
+8.24% |
| 2022-12-31 | CN¥3.71 Billion ≈ $543.41 Million |
-6.93% |
| 2021-12-31 | CN¥3.99 Billion ≈ $583.85 Million |
-3.75% |
| 2020-12-31 | CN¥4.15 Billion ≈ $606.61 Million |
-1.22% |
| 2019-12-31 | CN¥4.20 Billion ≈ $614.11 Million |
+82.22% |
| 2018-12-31 | CN¥2.30 Billion ≈ $337.02 Million |
+17.59% |
| 2017-12-31 | CN¥1.96 Billion ≈ $286.61 Million |
+49.53% |
| 2016-12-31 | CN¥1.31 Billion ≈ $191.68 Million |
+5.98% |
| 2015-12-31 | CN¥1.24 Billion ≈ $180.86 Million |
+160.41% |
| 2014-12-31 | CN¥474.63 Million ≈ $69.45 Million |
+12.30% |
| 2013-12-31 | CN¥422.64 Million ≈ $61.85 Million |
+3.18% |
| 2012-12-31 | CN¥409.62 Million ≈ $59.94 Million |
+5.10% |
| 2011-12-31 | CN¥389.74 Million ≈ $57.03 Million |
+8.92% |
| 2010-12-31 | CN¥357.81 Million ≈ $52.36 Million |
+222.93% |
| 2009-12-31 | CN¥110.80 Million ≈ $16.21 Million |
+21.15% |
| 2008-12-31 | CN¥91.45 Million ≈ $13.38 Million |
+37.19% |
| 2007-12-31 | CN¥66.66 Million ≈ $9.75 Million |
-- |
About Boai NKY Pharmaceuticals Ltd
Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP), Orarez, and in vitro diagnostic products, as well as invests in tumor drugs. It offers its products for pharmaceutical products, such as APIs and excipients; personal care products, including cosmetics, haircare, or… Read more